

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab-sci-crunch.org) on May 5, 2025

CHI3L1 antibody

RRID:AB_2040911

Type: Antibody

Proper Citation

(Abcam Cat# ab77528, RRID:AB_2040911)

Antibody Information

URL: http://antibodyregistry.org/AB_2040911

Proper Citation: (Abcam Cat# ab77528, RRID:AB_2040911)

Target Antigen: Human CHI3L1

Host Organism: rabbit

Clonality: polyclonal

Comments: validation status unknown, seller recommendations provided in 2012: Western Blot; Western Blot

Antibody Name: CHI3L1 antibody

Description: This polyclonal targets Human CHI3L1

Target Organism: human

Antibody ID: AB_2040911

Vendor: Abcam

Catalog Number: ab77528

Record Creation Time: 20241016T224154+0000

Record Last Update: 20241016T232212+0000

Ratings and Alerts

No rating or validation information has been found for CHI3L1 antibody.

No alerts have been found for CHI3L1 antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Hai L, et al. (2024) A clinically applicable connectivity signature for glioblastoma includes the tumor network driver CHI3L1. Nature communications, 15(1), 968.

Henon C, et al. (2024) Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs. Cell reports. Medicine, 5(6), 101582.

Jeon HM, et al. (2023) Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling. Cancer cell, 41(8), 1480.

Ghochani Y, et al. (2022) A molecular interactome of the glioblastoma perivascular niche reveals integrin binding sialoprotein as a mediator of tumor cell migration. Cell reports, 41(3), 111511.

Williams MM, et al. (2021) Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of ESR1-Mutant Breast Cancer. Cancer research, 81(3), 732.

Carrato C, et al. (2020) Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 26(24), 6600.